To develop evidence-based clinical algorithms for community acquired-acute respiratory tract infections CA-ARTI and assess the diagnostic accuracy and the clinical utility of point-of-care tests (POCT) for specific groups of patients, clinical findings, and settings
To develop evidence-based URS’s to support future development and implementation of rapid diagnostics to reduce antimicrobial resistance (AMR) for CA-ARTI, and to refine the methods and processes to make them applicable to POC diagnostic developments for other infectious disease indications
To create a technical roadmap that incorporates recommendations for short- and long-term goals to help companies and research institutions prioritize investment decisions in the field of CA-ARTI diagnostics.
https://www.value-dx.eu/wp-content/uploads/2024/04/Untitled-3.png9951488Leandrahttps://www.value-dx.eu/wp-content/uploads/2019/07/Logo-300x124.pngLeandra2024-04-22 11:33:552024-04-22 14:55:43PRUDENCE and ADEQUATE-paediatric studies: the final steps
https://www.value-dx.eu/wp-content/uploads/2023/08/shutterstock_1714915966-scaled.jpg14212560Leandrahttps://www.value-dx.eu/wp-content/uploads/2019/07/Logo-300x124.pngLeandra2024-02-02 12:34:072024-04-22 12:34:30VALUE-Dx paper on barriers and facilitators in pricing and funding policies of European countries impacting the use of point-of-care diagnostics for acute respiratory tract infections
https://www.value-dx.eu/wp-content/uploads/2023/11/Screenshot-2023-11-22-at-13.37.48.png656741Leandrahttps://www.value-dx.eu/wp-content/uploads/2019/07/Logo-300x124.pngLeandra2023-11-23 14:04:222023-11-23 14:05:15Progress and insights from the PRUDENCE and ADEQUATE trials